Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study.

Eleonora SaviCristoforo IncorvaiaElisa BoniMarina MauroSilvia PeveriValerio PravettoniOliviero QuerciaFederico ReccardiniMarcello MontagniLaura PessinaErminia Ridolo

Published in: PloS one (2017)

The data from CAP inhibition would suggest that the choice of either P. dominulus venom or mAP venom for VIT is appropriate in patients with CAP inhibition higher than 70%, but the clinical data show the same odds of protection from stings using for VIT P. dominulus or mAP venom.

Keyphrases

end stage renal disease
electronic health record
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
clinical trial
high density
machine learning
double blind